As atherosclerosis is also likely exacerbated by maladaptive trained immunity, one could speculate that the protective effects of antibody‐mediated neutralization of IL‐1β in the CANTOS trial for the treatment of atherosclerosis10 might also include the inhibition of IL‐1‐dependent trained myelopoiesis in the bone marrow. This evidence concerns the gene IL1B and atherosclerosis.